Faasi 3, n=657. NSCLC, EGFR -mut. (exon 19 del tai L858R), edennyt osimertinibin aikana. Randomointi 2:2:1: amivantamabi – lazertinibi – kemoterapia vs. kemoterapia vs. amivantamabi – kemoterapia. Amivantamabi on EGFR – MET bispef. vasta-aine ja lazertinibi on 3. sukupolven TKI.

PFS 8.3 kk, HR 0.48 (ami-laz-kemo) vs. 6.3 kk HR 0.44 (ami-kemo) vs. 4.2 kk [kemo], p<0.001 molemmissa tutkimushaaroissa vs. kemo.

ORR 64 % vs. 63 % vs. 36 %, p<0.001.

Intrakraniaalivasteet myös parempia tutkimushaaroissa (PFS 12.5 kk vs. 12.8 kk vs. 8.3 kk)

https://www.annalsofoncology.org/article/S0923-7534(23)04281-3/fulltext Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study